Novo Holdings considers sale of Xellia Pharmaceuticals
Novo Nordisk Foundation's investment company is examining opportunities for the sale of Xellia Pharmaceuticals.
BY MARKETWIRE, TRANSLATED BY CATHERINE BRETT
Sources have told Bloomberg News that Novo Holdings is currently investigating its options for a possible sale of Xellia Pharmaceuticals, which is headquartered in Amager, Copenhagen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
